Filgrastim and pegfilgrastim: risk of capillary leak syndrome

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
11 December 2014

Abstract

Capillary leak syndrome (CLS) has been reported in recipients of filgrastim, including patients undergoing chemotherapy and a healthy donor undergoing peripheral blood progenitor-cell mobilisation; it has also been reported in recipients of pegfilgrastim undergoing chemotherapy. Prescribers should monitor patients and healthy donors for signs and symptoms of capillary leak syndrome (CLS), and should give standard symptomatic treatment immediately if symptoms occur.